Form 8-K
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 19, 2010

NuPathe Inc.
(Exact name of registrant as specified in its charter)

         
Delaware   001-34836   20-2218246
(State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
     
227 Washington Street
Suite 200
Conshohocken, Pennsylvania
   19428
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (484) 567-0130

 
Not Applicable
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

1

 

Item 7.01 Regulation FD Disclosure.

On October 19, 2010, NuPathe Inc.® issued a press release announcing certain top-line results from a 12 month open-label, safety trial for Zelrix™, as well as the development of an in vitro analytical testing method for Zelrix. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d)     Exhibits.

The following press release is furnished as Exhibit 99.1 to this Form 8-K pursuant to Item 7.01 and shall not be deemed to be “filed”:

99.1     Press release, dated October 19, 2010, issued by NuPathe Inc.

 
 

 

- 2 -

 

2

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NUPATHE INC.

By:  /s/ Keith A. Goldan                                               
Keith A. Goldan
Chief Financial Officer

Dated: October 19, 2010

 

- 3 -

 

3

 

 

EXHIBIT INDEX

     
 
    
Exhibit No.
  Description of Exhibit
 
    
99.1
  Press release, dated October 19, 2010, issued by NuPathe Inc.

 

 

 

4